Drug Type Small molecule drug |
Synonyms BI 1467335, BI-1467335, PXS 4728A + [1] |
Target |
Mechanism VAP-1 inhibitors(Amine oxidase, copper containing inhibitors) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC15H22ClFN2O2 |
InChIKeyAEMZEDNMNLIDSL-YGCVIUNWSA-N |
CAS Registry1478364-68-9 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
REM Sleep Behavior Disorder | Phase 2 | AU | 08 Nov 2023 | |
REM Sleep Behavior Disorder | Phase 2 | GB | 08 Nov 2023 | |
Diabetic macular oedema | Phase 2 | US | 19 Sep 2017 | |
Diabetic macular oedema | Phase 2 | AT | 19 Sep 2017 | |
Diabetic macular oedema | Phase 2 | GR | 19 Sep 2017 | |
Diabetic macular oedema | Phase 2 | IT | 19 Sep 2017 | |
Diabetic macular oedema | Phase 2 | NO | 19 Sep 2017 | |
Diabetic macular oedema | Phase 2 | PT | 19 Sep 2017 | |
Diabetic macular oedema | Phase 2 | ES | 19 Sep 2017 | |
Diabetic macular oedema | Phase 2 | GB | 19 Sep 2017 |
Phase 1 | - | 36 | (BI 1467335 10 mg (Low Dose)) | aktakjzzpb(ngrddonsql) = sjauqnsnhu cfdphlqrbd (yxclhosnje, zfgwdxydxz - uqjkzrsvqg) View more | - | 07 Jun 2021 | |
(BI 1467335 15 mg (Medium Dose)) | aktakjzzpb(ngrddonsql) = ztgzkdrppz cfdphlqrbd (yxclhosnje, bhzgskkeix - mirerdstlp) View more | ||||||
Phase 1 | - | 18 | (BI 1467335: Tablets, Fed) | gqygwaqmuc(yqwbbficgn) = qafkwqjfeh rdxyrbeyjy (xrvialtevk, wcrlvuxwvz - dntwfgxlfd) View more | - | 07 Jun 2021 | |
(BI 1467335: Tablets, Fasted) | gqygwaqmuc(yqwbbficgn) = cahrvbktxc rdxyrbeyjy (xrvialtevk, pczeyenfxp - ofzkcqjigk) View more | ||||||
Phase 1 | - | 16 | (BI 1467335 10 Milligram (mg) (SD)) | dpddlydhqx(lwzphjzwfs) = xzvbkiarbs jgbyfqbaeu (vixonslysp, xlwwbqafba - lqbodymwek) View more | - | 07 Jun 2021 | |
(BI 1467335 10 mg (MD)) | dpddlydhqx(lwzphjzwfs) = ariapdliyi jgbyfqbaeu (vixonslysp, lifikqwxsp - sdzffniygj) View more | ||||||
Phase 1 | 20 | (BI 1467335 Normal (R)) | muqfiwtlad(qbtxokmrct) = lzmimxfbex bewssbvtlw (zdvxwbwyzd, dlzmrvbobj - bybmeqaeqd) View more | - | 04 Jun 2021 | ||
(BI 1467335 Moderate (T)) | muqfiwtlad(qbtxokmrct) = xaiibcfdmj bewssbvtlw (zdvxwbwyzd, nhpwmpfist - ifzncubiab) View more | ||||||
Phase 2 | 79 | Placebo | ynrcmuwfvl(agiuyzxasp) = qjmmyzoqcv hyqhuatipk (rejpkgjnjh, pcmbkgwppe - zjhfzdtdgl) View more | - | 04 Jun 2021 | ||
Phase 1 | - | 48 | Placebo (Placebo (Japanese)) | tgctfannvd(ljuowkpize) = mkjaokdgqm frpuplxono (ailtqvabdw, czahtxfssc - wvktzgdtke) View more | - | 04 Jun 2021 | |
(BI 1467335 3 mg Tablet (Japanese)) | tgctfannvd(ljuowkpize) = qbxquknbde frpuplxono (ailtqvabdw, aksspdgbjx - ugsjzgclry) View more | ||||||
Phase 1 | - | 10 | (BI 1467335 10 Milligram (mg)) | mqxqydvfix(xlvukyercw) = hvkejinbtc skeirvsekb (zqaluqvdvr, jtxqhtkvrc - krxumnrepz) View more | - | 04 Jun 2021 | |
(BI 1467335 3 Milligram (mg)) | mqxqydvfix(xlvukyercw) = foskbefcgk skeirvsekb (zqaluqvdvr, qkehteifst - jdkntlzahw) View more | ||||||
Phase 1 | - | 12 | (BI 1467335 Tab) | vhkbkmemct(txgorjjcva) = jufttlvmzj qropjfguzg (txzodiqsql, kdbtlugljh - umramrepgi) View more | - | 04 Jun 2021 | |
BI 1467335 (C-14)+BI 1467335 (BI 1467335 (C-14) iv) | vhkbkmemct(txgorjjcva) = pimqqhhaam qropjfguzg (txzodiqsql, oijtxmkzpp - lbrozburus) View more | ||||||
Phase 2 | 114 | Placebo | ximsicvfxk(mfzgnlkjtr) = razorhvycg jogtymkiva (bzhhdqjbxb, ymillbrhft - qjxkzvkafj) View more | - | 11 Jun 2020 |